The note, issued on February 25, 2025, was purchased by the Delaware limited partnership for $250,000. The note carries an annual interest rate of 6.0% and allows Channel Therapeutics the option to ...
Channel Therapeutics Corp (NYSE American: CHRO), a biotech firm specializing in biological products with a market capitalization of $12.36 million, has entered into an unsecured promissory note ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback